Disclosed herein are photoactivable fluorophores comprising one or more thiocarbonyl groups as well as conjugates and compositions thereof. The present disclosure also provides methods of preparing photoactivatable fluorophores as well as methods of imaging using the photoactivatable fluorophores, conjugates, and compositions of the present disclosure.

A cross-linker composition, a resin composition, a curable composition, a method of making thereof, and articles produced therefrom are provided. The cross-linker composition can be formed from by contacting a diethanolamine with a dialkylsquarate to form the cross-linker composition. The resin composition can be formed by contacting the cross-linker composition with an isocyanate. The curable composition can be formed by contacting the resin composition with an amine.

A cross-linker composition, a resin composition, a curable composition, a method of making thereof, and articles produced therefrom are provided. The cross-linker composition can be formed from by contacting a diethanolamine with a dialkylsquarate to form the cross-linker composition. The resin composition can be formed by contacting the cross-linker composition with an isocyanate. The curable composition can be formed by contacting the resin composition with an amine.

The present invention relates inter alia to organic compounds, compositions, formulations and electronic devices.

The present invention relates inter alia to organic compounds, compositions, formulations and electronic devices.

The present invention includes fused tetraphenylene compounds that may be used as charge transporters, hosts or emitters in OLEDs.

The present invention includes fused tetraphenylene compounds that may be used as charge transporters, hosts or emitters in OLEDs.

Provided herein are anti-fibrotic compounds, in particular those of Formula (I), that inhibit the TGF-beta signaling pathway. Also provided are pharmaceutical compositions comprising the anti-fibrotic compounds, and methods of treating diseases or conditions associated with fibrosis, inflammation, and benign or malignant neoplastic diseases in a subject by administering a compound KIN or composition described herein. (Formula (I))

Provided herein are anti-fibrotic compounds, in particular those of Formula (I), that inhibit the TGF-beta signaling pathway. Also provided are pharmaceutical compositions comprising the anti-fibrotic compounds, and methods of treating diseases or conditions associated with fibrosis, inflammation, and benign or malignant neoplastic diseases in a subject by administering a compound KIN or composition described herein. (Formula (I))

This invention relates to a method for producing an alkenyl 1-aminocyclopropane-1-carboxylic acid of Formula I wherein R.sup.1 is a protecting group, n is an integer between 1 and 10, and A and B are chiral centres such that when A is S, B is R and when A is R, B is S. The method comprises a stereoselective formation of the cyclopropane moiety by cycloaddition onto a double bond, in a molecule comprising a chiral template, Formula lc. Further provided is the use of Formula I in the production of stapled peptides.

##STR00001##